Skip to main content
main-content

Diabetes medications


Browse the latest news, expert commentary, and educational content on diabetes medications.


SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

02-24-2021 | Semaglutide | News

STEP 3: Semaglutide boosts weight loss during intensive behavioral therapy

Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.

02-22-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

02-18-2021 | COVID-19 | News

Metformin among factors linked to favorable COVID-19 outcomes

The latest report from the CORONADO study reveals factors predictive of home discharge within 28 days among people with diabetes hospitalized with COVID-19, as well as those linked to mortality risk.

02-17-2021 | Empagliflozin | News

Direct ‘decongestion’ effect shown for empagliflozin in HF

Empagliflozin treatment significantly reduces pulmonary artery blood pressure in patients with heart failure, show findings from the randomized EMBRACE-HF trial.

02-16-2021 | Liraglutide (obesity) | News

Liraglutide warrants further investigation in obese people with severe mental illness

Findings from a pilot study suggest that the GLP-1 receptor agonist liraglutide might be beneficial for the management of obesity in people with schizophrenia, schizoaffective disorder, or first-episode psychosis.

02-11-2021 | Semaglutide | Video | Article

STEP 1: Semaglutide for weight loss

Lead author of the STEP 1 trial, John Wilding, discusses the findings and what they may mean for the treatment of people with obesity (5:42)

02-11-2021 | Semaglutide | At a glance | Article

A quick guide to the STEP trials

Read our round-up the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.

02-11-2021 | Semaglutide | News

STEP 1: Semaglutide promotes substantial weight loss in people without diabetes

Findings of the STEP 1 study show marked weight loss in people with obesity but without type 2 diabetes during over a year of treatment with a high dose of semaglutide.

02-10-2021 | Empagliflozin | News

Adding empagliflozin to closed-loop insulin may reduce need for carbohydrate counting

Among people with type 1 diabetes, adding the SGLT2 inhibitor empagliflozin to an automated insulin delivery system may allow replacement of carbohydrate counting with a simple meal announcement, suggest findings from a pilot randomized trial.

02-09-2021 | Empagliflozin | News

Empagliflozin gains occur on top of neprilysin inhibitor benefits in HF

Findings from EMPEROR-Reduced show that people with heart failure benefit from SGLT2 inhibition even if they are already taking a neprilysin inhibitor.

02-08-2021 | COVID-19 | News

No need to discontinue DPP-4 inhibitors during hospitalization for COVID-19

Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

02-03-2021 | Older adults | News

Overtreatment linked to poor outcomes for older adults with diabetes

Researchers find that older adults with diabetes are frequently treated to an intensive glycemic target, putting them at risk for poor outcomes, particularly when high-risk agents are used.

01-28-2021 | Diabetes prevention | News

Dapagliflozin may reduce diabetes risk in people with heart failure

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

01-21-2021 | SGLT2 inhibitors | News

Meta-analysis underscores individual risk profile impact on GLP-1, SGLT2 benefits

A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits